

msb 8-4-99


FORM PTO-1619A  
Expires 06/30/99  
OMB 0651-0027

08-09-1999

REC



101112227



TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

**Submission Type**

- ☒ New
- ☐ Resubmission (Non-Recordation)  
Document ID#
- ☐ Correction of PTO Error  
Reel #  Frame #
- ☐ Corrective Document  
Reel #  Frame #

**Conveyance Type**

- ☐ Assignment ☒ Security Agreement
- ☐ License ☐ Change of Name
- ☐ Merger ☐ Other

U.S. Government  
(For Use ONLY by U.S. Government Agencies)

- ☐ Departmental File ☐ Secret File

**Conveying Party(ies)**

- ☐ Mark if additional names of conveying parties attached
- Name (line 1)  Execution Date  
Month Day Year  
06/30/99

- Name (line 2)
- Second Party**
- Name (line 1)  Execution Date  
Month Day Year
- Name (line 2)

**Receiving Party**

- ☐ Mark if additional names of receiving parties attached

- Name (line 1)
- Name (line 2)
- Address (line 1)
- Address (line 2)
- Address (line 3)     
City State/Country Zip Code

If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

**Domestic Representative Name and Address**

Enter for the first Receiving Party only.

- Name
- Address (line 1)
- Address (line 2)
- Address (line 3)
- Address (line 4)


08/05/1999 MTHA11 00000178 4931288  
01 FC:581 2200.00 00

FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:  
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

PATENT  
REEL: 010164 FRAME: 0083  
REEL: 010164 FRAME: 0083



**Correspondent Name and Address**

**Area Code and Telephone Number**

(212) 309-6870

**Name** Richard S. Petretti, Esq.

**Address (line 1)** Morgan, Lewis & Bockius LLP

**Address (line 2)** 101 Park Avenue

**Address (line 3)** New York, NY 10178

**Address (line 4)**

**Pages**

Enter the total number of pages of the attached conveyance document including any attachments.

# 21

**Application Number(s) or Patent Number(s)** Please see ☒ **Mark if additional numbers attached**

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

**Patent Application Number(s)**

**Patent Number(s)**



If this document is being filed together with a new Patent Application, enter the date the patent application was signed by the first named executing inventor.

Month Day Year

**Patent Cooperation Treaty (PCT)**

Enter PCT application number

only if a U.S. Application Number has not been assigned.

PCT

PCT

PCT

PCT

PCT

PCT

**Number of Properties**

Enter the total number of properties involved.

# 55

**Fee Amount**

Fee Amount for Properties Listed (37 CFR 3.41): \$

**Method of Payment:**

Enclosed ☒

Deposit Account ☐

**Deposit Account**

(Enter for payment by deposit account or if additional fees can be charged to the account.)

**Deposit Account Number:**

# 13-4520

**Authorization to charge additional fees:**

Yes ☒

No ☐

**Statement and Signature**

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Richard S. Petretti

**Name of Person Signing**

**Signature**

June 27, 1999

**Date**

BTG Licence Agreement Dated October 1, 1992 (PGE2 Pessary)

**Process for Hydrogel - Invention 1118472 (II)**

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United States	4931288	6/5/07
United States	5017382	5/21/08

**Preparation of Particulate Gel - Invention 1121960**

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United States	4542176	9/17/02

**Retrievable Device - Invention 1136216**

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United States	5269321	12/14/10

BTG Option Agreement dated March 31, 1997 (Oromucosal Products)

**Polyethylene Oxide Composition (I)**

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United States	4894238	1/16/90
United States	5079009	1/7/92

**Polyethylene Oxide Composition (II)**

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United States	4931288	6/5/90

United States

5017382

5/21/91

BTG Option Agreement dated March 31, 1997 (Oromucosal Products)

**Release Composition Structure**

<u>Country</u>	<u>Patent Number</u>	<u>Grant Date</u>
United States	4814182	3/21/89

AndroSolutions Development and License Agreement

<u>Country</u>	<u>Patent Number</u>	<u>Grant Date</u>
United States	ASI 60/068,294	Pending

[continue on next page]

## Multivalent guanyldrazone-related cases (US docket)

0102	08/315,170	Guanyldrazones and their use to treat inflammatory conditions	# 5,599,984
	29SEP1994		04FEB1997
0103	08/483,568	Guanyldrazones and their use to treat inflammatory conditions	# 5,750,573
	05JUN1995		12MAY1998
0103 A	08/472,003	Guanyldrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 B	08/472,919	Guanyldrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 C	08/471,696	Guanyldrazones and their use to treat inflammatory conditions	# 5,753,684
	06JUN1995		19 MAY1998
0103 D	08/471,305	Guanyldrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 E	08/471,124	Guanyldrazones and their use to treat inflammatory conditions	# 5,859,062
	06JUN1995		12JAN1999

0103 G	08/472,004	Guanyldrazones and their use to treat inflammatory conditions	# 5,849,794
	06JUN1995		15DEC1998
0103 H	08/479,050	Guanyldrazones and their use to treat inflammatory conditions	pending
	06JUN1995		

0104	08/532,305	Guanyldrazones and their use to treat inflammatory conditions	# 5,854,289
	15APR1996		29DEC1998

0105	08/970,973	Guanyldrazones useful for treating diseases associated with T cell activation	pending
	14NOV1997		
0106	08/780,311	Complexes and combinations of fetuin with therapeutic agents	pending
	08JAN1997		
end of section			

## Macrophage Migration Inhibitory Factor-related cases (US docket)

0202	08/243,342	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0203	08/462,350	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	05JUN1995		
0203 A	08/470,901	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 B	08/479,901	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 C	08/479,090	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity using soluble MIF receptor	pending
	06JUN1995		
0203 D	08/471,705	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		

0203 F	08/471,546	Combination method for treating diseases caused by cytokine-mediated toxicity	pending
	06JUN1995		
0203 G	08/471,586	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0204	08/602,929	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	16FEB1996		
0205	08/738,947	Therapeutic uses of factors which inhibit or neutralize MIF activity	pending
	24OCT1996		
end of section			

NLS-based HIV inhibitor-related cases (US docket)			
0301	08/369,830	Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,574,040
	06JAN1995		12 NOV1996
0302	08/463,405	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,733,932
	5JUN1995		31MAR1998
0302 A	08/471,797	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,703,086
	6JUN1995		30DEC1997
0302 B	08/470,103	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,620,983
	6JUN1995		15APR1997
0303	08/584,857	Compounds for treating infectious diseases	# 5,840,893
	5JAN1996		24NOV 1998
0304	08/732,653	Compounds and methods of use to treat infectious diseases	pending
	15OCT1996		
0305	08/912,076	HIV nuclear localization inhibitors	# 5,806,058
	15AUG1997		15SEP1993
0306	08/911,883	HIV matrix protein tyrosine position 29 pocket binders	# 5,849,793
	15AUG1997		15DEC1998

Fibrocyte-related cases (US docket)			
0401	08/023,290	Blood-borne mesenchymal cells	# 5,654,186
	26FEB1993		05AUG1997
0401 A	08/487,116	Blood-borne mesenchymal cells	pending
	07JUN1995		
0401 B	08/488,241	Blood-borne mesenchymal cells	# 5,846,796
	07JUN1995		8DEC1998
0402	08/488,111	Blood-borne mesenchymal cells	# 5,804,446
	07JUN1995		8SEP1998
0402 A	08/488,112	Blood-borne mesenchymal cells	pending
	07JUN1995		
0403	08/970,971	Process for isolating blood-borne fibrocytes	pending
	14NOV1997		
0404	08/828,415	Fibrocyte-based vaccine formulations	pending
	28MAR1997		
end of section			



## Cyclophilin receptor-related HIV inhibition-related cases

0501	08/615,933	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	# 5,840,305
	14MAR1996		24NOV1998

## Spermine antagonists-related cases

0601	08/874,681	Immunotherapeutic anti-cancer pharmaceutical compositions	pending
	13JUN1997		--
0602	08/932,871	Prevention of pregnancy miscarriages	pending
	18SEP1997		
0603	09/096,761	Immunotherapeutic anti-cancer pharmaceutical compositions	pending
	12JUN1998		

## iPFK2 and the Warburg effect-related cases

0901	08/961,578	Inducible phosphofructokinase and the Warburg effect	pending
	31OCT1997		
0902	09/183,846	Inducible phosphofructokinase and the Warburg effect	pending
	30OCT1998		
0903 P	60/130,049	Synthetic process for five-membered polyols and substituted sugar analogs	pending
	19APR1999		

## HMG1/amphotericin antagonists-related cases (US and foreign dockets)

1201	09/248,574	Antagonists of HMG1 for treating inflammatory conditions	pending
	11FEB1999		
end of section			

## PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT dated as of June 29, 1999 (as amended, modified or supplemented from time to time, this "Patent Security Agreement"), is made by and between Cytokine PharmaSciences, Inc. a Delaware corporation (the "Pledgor"), and Merrill Lynch Business Financial Services Inc., a Delaware corporation (the "Secured Party").

### R E C I T A L S:

WHEREAS, the Pledgor, now owns or holds and may hereafter acquire or hold, as owner, licensee or sublicensee, Patents (defined as all of the following: all United States and foreign patents and patent applications, whether now existing or hereafter arising or acquired and all reissues, continuations, continuations-in-part or extensions thereof) including, without limitation, the Patents listed on Schedule A annexed hereto, as such Schedule may be amended from time to time by the addition of Patents subsequently arising or acquired;

WHEREAS, the Pledgor was formerly known as Cytokine Networks, Inc. and is the successor-by-merger to PharmaSciences, Inc., a Delaware corporation ("Old PharmaSciences");

WHEREAS, the Pledgor is a party to the WCMA Reducing Revolver Loan and Security Agreement No. 871-07R72 dated as of June<sup>30</sup>, 1999 (as the same may be amended, supplemented or otherwise modified, renewed or replaced from time to time, the "Loan Agreement") originally entered into by Old PharmaSciences and the Secured Party, to which reference is made for definitions of capitalized terms used and not otherwise defined herein; and

WHEREAS, pursuant to the terms of the Loan Agreement, the Pledgor has granted the Secured Party a security interest in all of the Pledgor's right, title and interest in and to certain Collateral including certain Patent Collateral (as hereinafter defined), to secure the due and punctual payment and performance of the Obligations.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Pledgor does, as security for the due and punctual payment and performance of the Obligations, hereby grant to the Secured Party a continuing security interest in all of the Pledgor's right, title and interest in, to and under the following (all of the following items or types of property being collectively referred to herein as the "Patent Collateral"), whether presently existing or hereafter arising or acquired:

- (i) each Patent, including, without limitation, each Patent and Patent application referred to in Schedule A annexed hereto (which Schedule includes Patents Licensed to Pledgor pursuant to licenses listed on Schedule B hereto);
- (ii) each Patent license, including, without limitation, each Patent license referred to in Schedule B annexed hereto, to the extent such Patent license does not prohibit the licensee from assigning or granting a security interest in its rights thereunder; and
- (iii) all products and proceeds of, and income from, any of the foregoing, including, without limitation, and subject to the provisions hereinafter set forth, any claim by the Pledgor against third parties for past, present or future infringement or dilution of any Patent or any Patent licensed under any Patent license.

but, subject to Pledgor's obligations under Section 4.4(l) of the Loan Agreement, excluding any rights under any license or other agreement relating to Patent Collateral which by its terms prohibits the creation or enforcement of a lien or security interest in Pledgor's rights thereunder, provided, further that any proceeds of or income derived from any such excluded rights shall nevertheless be included in the Patent Collateral.

The Pledgor agrees to deliver updated copies of Schedule A and Schedule B to the Secured Party at the end of any quarter in which the Pledgor applies for the registration of, registers or otherwise acquires (or Pledgor first becomes aware that any licensor required to be listed on Schedule B hereto has applied for the registration of, registered or otherwise acquired) any Patent not listed on Schedule A hereto (and required to be listed thereon) or enters into any Patent license not listed on Schedule B hereto, and to duly and promptly execute and deliver, or have duly and promptly executed and delivered, at the cost and expense of the Pledgor, such further instruments or documents (in form and substance satisfactory to the Secured Party) and promptly perform, or cause to be promptly performed, any and all acts, in all cases, as may be necessary, proper or advisable from time to time, in the reasonable judgment of the Secured Party, to carry out the provisions and purposes of the Loan Agreement and this Patent Security Agreement, and to provide, perfect and preserve the Liens of the Secured Party under the Loan Agreement and this Patent Security Agreement, in the right, title and interest of Pledgor in the Patent Collateral or any portion thereof.

The Pledgor agrees that if any Person, firm, corporation or other entity shall do or perform any acts which the Secured Party believes constitute an infringement of any Patent which is the subject of this Patent Security Agreement, or violate or infringe any right of the Pledgor or the Secured Party therein or if any Person, firm, corporation or other entity shall do or perform any acts which the Secured Party believes constitutes an unauthorized or unlawful use thereof, then and in any such event, upon 30 days' prior written notice to Pledgor (or if an Event of Default is continuing, then without such notice), the Secured Party, subject to the rights of any licensor under a license listed on Schedule B hereto or any provision to the contrary in any

applicable license or sublicense agreement covering the applicable Patent Collateral, may take such steps and institute such suits or proceedings as the Secured Party may deem advisable or necessary to prevent such acts and conduct and to secure damages and other relief by reason thereof, and to generally take such steps as may be advisable or necessary or proper for the full protection of the rights of the parties. Subject to the rights of any licensor under a license listed on Schedule B hereto or any provision to the contrary in any applicable license or sublicense agreement covering the applicable Patent Collateral, the Secured Party may take such steps or institute such suits or proceedings in its own name or in the name of the Pledgor or in the names of the parties jointly. The Secured Party hereby agrees to give the Pledgor notice of any steps taken, or any suits or proceedings instituted, by the Secured Party pursuant to this paragraph.

This security interest is granted in conjunction with the security interests granted to the Secured Party pursuant to the Loan Agreement. The Pledgor does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Patent Collateral made and granted hereby are subject to, and are more fully set forth in, the Loan Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

This Patent Security Agreement is made for collateral purposes only. At such time as all of the Obligations shall have been fully and indefeasibly paid and performed and the commitments of the Secured Party to make advances under the Loan Agreement shall have terminated, the Secured Party shall execute and deliver to the Pledgor, at the Pledgor's expense, without representation, warranty or recourse, all releases and reassignments, termination statements and other instruments as may reasonably be requested in order to terminate the security interest of the Secured Party in the Patent Collateral, subject to any disposition thereof which may have been made by the Secured Party pursuant to the terms hereof or of the Loan Agreement.

So long as no Event of Default shall have occurred and be continuing, and subject to the various provisions of the Loan Agreement and the Additional Agreements to which it is a party, the Pledgor may use the Patent Collateral in any lawful manner.


**THIS PATENT SECURITY AGREEMENT SHALL IN ALL RESPECTS BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF ILLINOIS WHICH ARE APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE.**

[Signature Page Follows]

IN WITNESS WHEREOF, the Pledgor has caused this Patent Security Agreement to be duly executed as of June 30, 1999.

**PLEDGOR:**

CYTOKINE PHARMASCIENCES, INC.

By:   
Name: George J. Todaro  
Title: Vice President  
Four Tower Bridge  
200 Barr Harbour Drive, Suite 400  
West Conshohocken, PA 19428-2978  
Attention: DENNIS F. WILLSON  
Telephone No. 610-941-2747  
Telecopy No. 610-940-0458

**SECURED PARTY:**

MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC.


By:   
Name: Brian R. Connor  
Title: Assistant Vice President  
222 North LaSalle Street, 17th Floor  
Chicago, IL 60601  
Attention: Dan McHugh  
Telephone No. (312) 269-4483  
Telecopy No. (312) 268-1378

Exhibit A -  
List of Patents

Pharma Sciences

BTG License Agreement Dated October 1, 1992 (PGF2 Pessary).

Process for Hydrogel - Invention 1118472 (II)

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United Kingdom	2047094	3/21/00
Australia	537741	3/21/00
Austria	EPO016654	3/20/00
Belgium	EPO016654	3/20/00
France	EPO016654	3/20/00
Germany	EPO016654	3/20/00
Hong Kong	85/798	3/20/00
Italy	EPO016654	3/20/00
Japan	1668238	3/21/00
Luxembourg	EPO016654	3/20/00
Netherlands	EPO016654	3/20/00
New Zealand	193221	3/21/00
Singapore	85/558	3/20/00
South Africa	80/1659	3/21/00
Sweden	EPO016654	3/20/00
United States	4931288	6/5/07
United States	5017382	5/21/08

Preparation of Particulate Gel - Invention 1121960

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United Kingdom	2100269	6/10/02
Belgium	EPO068684	6/10/02
Canada	1239724	7/25/05
France	EPO068684	7/10/02
Germany	EPO068684	7/10/02
Italy	EPO068684	7/10/02
Japan	1840054	6/12/02
Netherlands	EPO068684	6/10/02
Sweden	EPO068684	6/10/02
Switzerland	EPO068684	6/10/02
United States	4542176	9/17/02

Retrievable Device - Invention Number 1136216

<u>Country</u>	<u>Patent Number</u>	<u>Expiry Date</u>
United Kingdom	2254002	1/16/11
EPC*	92306296.2	7/9/12
Japan	2909477	7/9/12
Singapore	9691669-7	Unknown
United States	5269321	12/14/10

\* EP allowed 28 November 1997

List of Patents (Continued)

BTG Option Agreement dated March 31, 1997 (Oromucosal Products)

Polyethylene Oxide Composition (I)

<u>Country</u>	<u>Patent Number</u>	<u>Grant Date</u>
United Kingdom	2047093	12/7/83
Australia	537740	10/25/84
Austria	EPO016652	8/21/85
Belgium	EPO016652	8/21/85
France	EPO016652	8/21/85
Germany	EPO016652	8/21/85
Hong Kong	85/797	10/17/85
Italy	EPO016652	8/21/85
Japan	1667319	5/29/92
Luxembourg	EPO016652	8/21/85
Netherlands	EPO016652	8/21/85
New Zealand	193222	Unknown
Singapore	85/559	1/15/86
South Africa	80/1654	10/28/81
Sweden	EPO016652	8/21/85
Switzerland	EPO016652	8/21/85
United States	4894238	1/16/90
United States	5079009	1/7/92

Polyethylene Oxide Composition (II)

<u>Country</u>	<u>Patent Number</u>	<u>Grant Date</u>
Australia	537741	10/25/84
Austria	EPO016654	9/11/85
Belgium	EPO016654	9/11/85
France	EPO016654	9/11/85
Germany	EPO016654	9/11/85
Hong Kong	85/798	10/19/85
Italy	EPO016654	9/11/85
Japan	1668238	5/29/92
Luxembourg	EPO016654	9/11/85
Netherlands	EPO016654	9/11/85
New Zealand	193221	2/7/85
Singapore	85/558	1/15/86
South Africa	80/1659	10/28/81
Sweden	EPO016654	9/11/85
Switzerland	EPO016654	9/11/85
United States	4931288	6/5/90
United States	5017382	5/21/91

PATENT

REEL: 010164 FRAME: 0097

REEL: 010164 FRAME: 0097

List of Patents (Continued)

BTG Option Agreement dated March 31, 1997 (Oromucosal Products)

Release Composition Structure

<u>Country</u>	<u>Patent Number</u>	<u>Grant Date</u>
United Kingdom	2143733	5/28/87
Canada	1242394	9/27/88
France	EPO132384	9/26/90
Germany	EPO132384	9/26/90
Italy	EPO132384	9/26/90
Japan	1931037	5/12/95
Sweden	EPO132384	9/26/90
United States	4814182	3/21/89

AndroSolutions Development and License Agreement

<u>Country</u>	<u>Patent Application Number</u>	<u>Grant Date</u>
United States	ASI 60/068,294	Pending



Exhibit B

PharmSciences

Patent License Agreements

1. Agreement dated October 1, 1992 with BTG plc (f/k/a British Technology Group Limited) for license to vaginal use of hydrogel technology (Note: This is the underlying license for the PGE2 pessary).
2. Option Agreement dated March 31, 1997 with BTG plc (f/k/a British Technology Group Limited) for license to oromucosal use of the hydrogel technology.
3. Development and License Agreement dated July 9, 1998 with AndroSolutions, Inc. for license to the AndroSolutions erectile dysfunction product.

CNI

Exhibit A: Rights under the following Patents and Patent Applications have been licensed PIMR to CNI under the Amended and Restated Research and License Agreement of December 1, 1996.

Format of information supplied for each patent or patent application listed in Exhibit A:

Descriptive name of "family" of related applications (US or Foreign docket)			
PIMR docket number	Application #	Title of application or patent	Status or patent #
	Filing date		Issue date
end of section			

Multivalent guanyldihydrazone-related cases (US docket)			
0101	08/164,540	Guanyldihydrazones and their use to treat cachexia and related conditions	abandoned
	21JAN1994		
0102	08/315,170	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,599,984
	29SEP1994		04FEB1997
0103	08/483,568	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,750,573
	05JUN1995		12MAY1998
0103 A	08/472,003	Guanyldihydrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 B	08/472,919	Guanyldihydrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 C	08/471,696	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,753,684
	06JUN1995		19 MAY1998
0103 D	08/471,305	Guanyldihydrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 E	08/471,124	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,859,062
	06JUN1995		12JAN1999
0103 F	08/470,076	Guanyldihydrazones and their use for treating inflammatory conditions	abandoned
	06JUN1995		
0103 G	08/472,004	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,849,794
	06JUN1995		15DEC1998
0103 H	08/479,050	Guanyldihydrazones and their use to treat inflammatory conditions	pending
	06JUN1995		
0103 I	08/471,711	Guanyldihydrazones and their use to treat inflammatory conditions	abandoned
	06JUN1995		
0104	08/632,305	Guanyldihydrazones and their use to treat inflammatory conditions	# 5,854,289
	15APR1996		29DEC1998
0105 P	60/031,061	Treatment of disorders related to T cell activation by interfering with p38 MAP kinase pathway	converted
	15NOV1996		
0105	08/970,973	Guanyldihydrazones useful for treating diseases associated with T cell activation	pending
	14NOV1997		
0106	08/780,311	Complexes and combinations of fetuin with therapeutic agents	pending
	08JAN1997		
end of section			

Multivalent guanylhydrazone-related cases (Foreign docket)			
0102WO	US95/00828	Guanylhydrazones for treating inflammatory conditions	filed national
	19JAN1995		
0102 AU	18350/95	Guanylhydrazones for treating inflammatory conditions	# 683,999
	19JAN1995		19JAN1998
0102 CA	2,181,689	Guanylhydrazones for treating inflammatory conditions	pending
	19JAN1995		
0102 CN	95192171.1	Guanylhydrazones for treating inflammatory conditions	pending
	20SEP1996		
0102 EP	95910110.6	Guanylhydrazones for treating inflammatory conditions	pending
	19JAN1995		
0102 JP	07-519690	Guanylhydrazones for treating inflammatory conditions	pending
	22JUL1996		
0102 MX	96 02874	Guanylhydrazones and their use for treating inflammatory conditions	pending
	19JUL1996		
0102 NZ	281400	Guanylhydrazones and their use for treating inflammatory conditions	# 281400
	19JAN1995		19JAN1998
0105WO	US97/20670	Guanylhydrazones useful for treating diseases associated with T-cell activation	filed national
	14NOV1997		
0105 EP	97948263.5	Guanylhydrazones useful for treating diseases associated with T-cell activation	pending
0106WO	US98/00390	Complexes and combinations of fetuin with therapeutic agents	pending
	08JAN1998		
end of section			

Macrophage Migration Inhibitory Factor-related cases (US docket)			
0201	08/063,399	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
	17MAY1993		
0202	08/243,342	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0203	08/462,350	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	05JUN1995		
0203 A	08/470,901	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 B	08/479,901	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 C	08/479,090	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity using soluble MIF receptor	pending
	06JUN1995		
0203 D	08/471,705	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 E	08/479,092	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
	06JUN1995		
0203 F	08/471,546	Combination method for treating diseases caused by cytokine-mediated toxicity	pending
	06JUN1995		
0203 G	08/471,586	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0204	08/602,929	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	16FEB1996		
0205	08/738,947	Therapeutic uses of factors which inhibit or neutralize MIF activity	pending
	24OCT1996		
end of section			

Macrophage Migration Inhibitory Factor-related cases (Foreign docket)			
0202WO	US94/05433	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	filed national
	16MAY1994		
0202 AU	68345/94	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	# 692159
	5SEP1998		5SEP1998
0202 CA	2,163,211	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0202 EP	94916785.2	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0202 JP	6-525764	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0209WO	US97/02448	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	filed national
	14FEB1997		
0204 CA	CA2218364	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	14FEB1997		
0204 EP	97905997.9	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	24OCT1997		
0204 JP	9-529544	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	14FEB1997		
0205WO	US97/19924	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	filed national
	24OCT1997		
end of section			



NLS-based HIV inhibitor-related cases (Foreign docket)			
0303WO	US96/00486	Compounds and methods of use to treat infectious diseases	filed national
	05JAN1996		
0303 AU	47559/96	Compounds and methods of use to treat infectious diseases	pending
	13OCT1997		
0303 CA	2,218,561	Compounds and methods of use to treat infectious diseases	pending
	13OCT1997		
0303 EP	96903481.8	Compounds and methods of use to treat infectious diseases	pending
	08OCT1997		
0304 JP		Compounds and methods of use to treat infectious diseases	pending
0304WO	97/19071	Compounds and methods of use to treat infectious diseases	filed national
	15OCT1997		
0305WO	US98/16814	HIV nuclear localization inhibitors	pending
	13AUG1998		
0306WO	US98/16923	HIV matrix protein tyrosine position 29 pocket binders	pending
	14AUG1998		
end of section			



Fibrocyte-related cases (US docket)			
0401	08/023,290	Blood-borne mesenchymal cells	# 5,654,186
	26FEB1993		05AUG1997
0401 A	08/487,116	Blood-borne mesenchymal cells	pending
	07JUN1995		
0401 B	08/488,241	Blood-borne mesenchymal cells	# 5,846,796
	07JUN1995		8DEC1998
0402	08/488,111	Blood-borne mesenchymal cells	# 5,804,446
	07JUN1995		8SEP1998
0402 A	08/488,112	Blood-borne mesenchymal cells	pending
	07JUN1995		
0403 P	60/031,259	Process for isolating blood-borne fibrocytes	converted
	15NOV1996		
0403	08/970,971	Process for isolating blood-borne fibrocytes	pending
	14NOV1997		
0404	08/828,415	Fibrocyte-based vaccine formulations	pending
	28MAR1997		
end of section			

Fibrocyte-related cases (Foreign docket)			
0401WO	US94/02850	Blood-borne mesenchymal cells	filed national
	16MAR1994		
0401 AU	65884/94	Blood-borne mesenchymal cells	# 6,934,41
	16MAR1994		05NOV1998
0401 CA	2185539	Blood-borne mesenchymal cells	pending
	16MAR1994		
0401 CN	94195107.3	Blood-borne mesenchymal cells	pending
	16MAR1994		
0401 EP	94913910.9	Blood-borne mesenchymal cells	pending
	2AUG1995		
0401 JP	7-523995	Blood-borne mesenchymal cells	pending
	15MAR1994		
0401 KP	7051171996	Blood-borne mesenchymal cells	pending
	19SEP1996		
0401 NZ	265435	Blood-borne mesenchymal cells	# 26435
	16MAR1994		08JAN1998
0404WO	US98/06094	Fibrocyte-based cellular therapy formulations	pending
	27MAR1998		
end of section			

Cyclophilin receptor-related HIV inhibition-related cases (US and foreign dockets)			
0501 P	60/013,185	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	converted
	12MAR1996		
0501	08/615,933	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	# 5,840,305
	14MAR1996		24NOV1998
0501WO	US97/03819	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	filed national
	12MAR1997		
0501 AU	25811/97	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	12MAR1997		
0501 CA	2,248,192	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	12MAR1997		
0501 EP	97917517.1	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	10OCT1997		
0501 JP	9-532773	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	12MAR1997		
end of section			

Spermine antagonists-related cases (US and foreign dockets)			
601	08/874,681	Immunotherapeutic anti-cancer pharmaceutical compositions	pending
	13JUN1997		--
602	08/932,871	Prevention of pregnancy miscarriages	pending
	18SEP1997		
603	09/096,761	Immunotherapeutic anti-cancer pharmaceutical compositions	pending
	12JUN1998		
604 P		Prevention of brain damage in stroke	pending
	13APR1999		
02WO	US98/19579	Prevention of pregnancy miscarriages	pending
	18SEP1998		
03WO	US98/12198	Immunotherapeutic anti-cancer pharmaceutical compositions	pending
	30JUL1998		
End of section			

iPFK2 and the Warburg effect-related cases (US and foreign dockets)			
0901	08/961,578	Inducible phosphofructokinase and the Warburg effect	pending
	31OCT1997		
0902	09/183,846	Inducible phosphofructokinase and the Warburg effect	pending
	30OCT1998		
0903 P	60/130,049	Synthetic process for five-membered polyols and substituted sugar analogs	pending
	19APR1999		
0902WO	US98/23155	Inducible phosphofructokinase and the Warburg effect	pending
	30OCT1998		
end of section			

MG1/amphoterin antagonists-related cases (US and foreign dockets)			
201	09/248,574	Antagonists of HMG1 for treating inflammatory conditions	pending
	11FEB1999		
end of section			

Exhibit B: Cytokine Networks, Inc. -- List of Licenses

All of the patent rights listed on Exhibit A are licensed to Cytokine Networks, Inc. ("CNI") pursuant to an Amended and Restated Research and License Agreement, dated as of December 1, 1996, between CNI and The Picower Institute for Medical Research.

STATE OF New York )  
 : ss.:  
COUNTY OF New York )

On the 30th day of June, in the year 1999 before me personally came  
George J. Todaro, to me known, who, being by me sworn, did say that he or she is the  
Vice President of Cytokine PharmaSciences, Inc., which corporation is  
described in, and executed, the above instrument, and that he or she signed his or her name by  
order of the Board of Directors of said corporation.

Soumaly Mitsri  
Notary Public

**SOUMALY MITSRI**  
**Notary Public, State of New York**  
**No. 01MI6012767**  
**Qualified in Queens County**  
**Certificate Filed in New York County**  
**Commission Expires 08/31/2022**